QualityStocksNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, welcomed final recommendations from Australia's Therapeutic Goods Administration regarding its Authorized Prescriber scheme for psilocybin and MDMA. The updated framework broadens eligible therapy teams, expands treatment settings beyond hospital environments and supports scaling of psychedelic-assisted therapy across Australia, where authorized psychiatrists can prescribe Optimi's GMP-compliant MDMA for PTSD and psilocybin for treatment-resistant depression. The company said the revised framework could accelerate adoption of psychedelic-assisted therapy by increasing workforce capacity, particularly in…